ArticleFrontiers in oncology2025
Factors influencing the outcomes of contrast-enhanced ultrasound in the detection of sentinel lymph nodes in breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze the influencing factors on the failure of sentinel lymph node (SLN) imaging in breast cancer by percutaneous injection contrast-enhanced ultrasound (CEUS). Methods: Clinical data including basic characteristics, medical history, ultrasound technical parameters, and laboratory findings were collected from the patients, and the pathological results of sentinel lymph node biopsy (SLNB) were used as the gold standard for all patients. Logistic regression was used to analyze all influencing factors. The performance of the model was assessed using the area under the receiver operating characteristic curve (AUC), P<0.05 was statistically significant. Nomogram was developed for the assessment of risk prediction. Results: A total of 1356 patients were included, of which 92.48% (1254/1356) had successful imaging and 7.52% (102/1356) had failed imaging. Logistic regression analysis showed that the quadrant location of tumor [(OR = 1.54, 95%CI: 1.01, 2.36)], the history of previous breast surgery [(OR = 3.05, 95%CI: 1.62, 5.72)], the metastasis of SLN [(OR = 2.68, 95%CI: 1.72, 4.15)], the history of neoadjuvant therapy [(OR = 2.90, 95% CI: 1.57, 5.37)], and the clinical prognostic stage [(OR = 3.50, 95% CI: 1.70, 7.22)] were the independent influencing factors of CEUS failure, with a statistically significant difference (P<0.05). The AUC of its predictive model in the training set was 0.72 (95% CI: 0.65-0.78), and the AUC of the predictive model in the validation set was 0.71 (95% CI: 0.61-0.81). Conclusions: The quadrant location of tumor, the history of previous breast surgery, the metastasis of SLN, the clinical prognostic stage and the history of previous neoadjuvant therapy were the independent influencing factors for the failure of CEUS for SLN imaging in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.